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On the lag phase in amyloid fibril formation
Paolo Arosio,a Tuomas P. J. Knowlesa and Sara Linse*b
The formation of nanoscale amyloid fibrils from normally soluble peptides and proteins is a common form of
self-assembly phenomenon that has fundamental connections with biological functions and human diseases.
The kinetics of this process has been widely studied and exhibits on a macroscopic level three characteristic
stages: a lag phase, a growth phase and a final plateau regime. The question of which molecular events take
place during each one of these phases has been a central element in the quest for a mechanism of amyloid
formation. In this review, we discuss the nature and molecular origin of the lag-phase in amyloid formation
by making use of tools and concepts from physical chemistry, in particular from chemical reaction kinetics.
We discuss how, in macroscopic samples, it has become apparent that the lag-phase is not a waiting time
for nuclei to form. Rather, multiple parallel processes exist and typically millions of primary nuclei form during
the lag phase from monomers in solution. Thus, the lag-time represents a time that is required for the
nuclei that are formed early on in the reaction to grow and proliferate in order to reach an aggregate
concentration that is readily detected in bulk assays. In many cases, this proliferation takes place through
secondary nucleation, where fibrils may present a catalytic surface for the formation of new aggregates. Fibrils
may also break (fragmentation) and thereby provide new ends for elongation. Thus, at least two – primary
nucleation and elongation – and in many systems at least four – primary nucleation, elongation, secondary
nucleation and fragmentation – microscopic processes occur during the lag phase. Moreover, these same
processes occur during all three phases of the macroscopic aggregation process, albeit at different rates
as governed by rate constants and by the concentration of reacting species at each point in time.
1. Introduction
Amyloid fibrils are observed in connection with more than
30 human diseases that are increasingly prevalent yet currently
incurable in the vast majority of cases. Well-known examples
are Amyloid Lateral Sclerosis (ALS), Alzheimer, Parkinson,
Huntington’s diseases and diabetes.1–4 Amyloid has also
emerged as a functional state in bacteria and fungi,5 as well
as in humans.6–8 Such functionality is thought to originate
from the fact that this stage offers a route towards the very tight
packing of proteins, which provides a stable storage environ-
ment, favorable mechanical properties and in some cases an
active catalytic surface for biosynthetic pathways.9 From an
ultra-structural point of view, amyloid fibrils are highly ordered
and elongated aggregates characterized at the molecular level
by the presence of an array of b-strands oriented perpendicu-
larly to the long axis of the fiber.10–12 Despite great variation in
sequence length and native, or natively unfolded, structure of
the precursor proteins, once assembled into amyloid fibrils, they
possess highly similar generic structures but with some variation
in local packing leading to morphological differences in, for
example, twist and internal lateral packing of b sheets (Fig. 1).
Thus, the amyloid structure is likely to represent an alter-
native stable structure for peptides and proteins accessible to
most if not all peptides and proteins.13,14 An individual amyloid
fibril is often formed from a protein with a given core sequence
and the structure is highly repetitive with the same inter-
protein contacts stabilizing the strands throughout the length
of the fibril.10,11 Amyloid deposits found in vivo in the context
of disease may, however, contain more than one protein, or
Fig. 1 Sketches of amyloid forming proteins associated to several human
diseases.
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protein variant, a fact that may be due to association of fibrils
or association of other proteins to the fibrils.15 Amyloid deposits
can also be rich in lipids.16 For many amyloid-forming proteins,
it has been found that monomers and full-length fibrils induce
limited or no toxicity to neurons or other cells.17 In contrast,
cell death can be induced by smaller aggregates of intermediate
sizes forming during the amyloid growth process.18,19 The size-
distribution and structures of these toxic assemblies are not
established, although some hints are emerging.20–23 It has also
been proposed that the aggregation process per se is toxic.24
In all cases, cellular toxicity is associated with an ongoing
assembly process in which free monomers are converted to
the amyloid state. From a biological and biomedical point of
view, it is therefore of key importance to understand the
amyloid formation process in terms of the underlying molecu-
lar events that define its mechanism.
Such a mechanistic understanding implies a dissection of
the overall aggregation process into its underlying composite
reactions, the microscopic steps. Moreover, important insights
may be gained by defining the rate constants governing each
microscopic step and determining the manner in which they
depend on protein sequence as well as on solution conditions
such as salt, pH, temperature, other proteins, membranes, and
species that inhibit protein aggregation.
One relevant feature of the aggregation process of amyloids
is the lag-phase that is commonly observed during the kinetics
of fibril formation. The molecular origin of this lag-phase has
historically attracted large attention because of the key mecha-
nistic information that is potentially contained in this macro-
scopic observable. In this review, after presenting the currently
available experimental evidences, we discuss the microscopic
mechanisms underlying the origin of the lag-phase, providing a
mechanistic framework to dissect information on the micro-
scopic aggregation steps from this measurable macroscopic
phase. We elucidate most of the concepts discussed in this
work using as an example the Alzheimer’s disease-associated
peptide Ab42, for which a detailed quantitative and mechanistic
picture of the aggregation process is now available. However, the
concept of lag-phase discussed here is general, and applies to
other amyloidogenic peptides and proteins.
2. Monomers, aggregates, fibrils,
oligomers and nuclei
The species observed to form as a consequence of protein
aggregation processes are commonly highly heterogeneous.
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Indeed, the overall reaction results in the conversion of mono-
meric soluble peptides or proteins into an array of aggregate
structures; in large part due to this significant level of hetero-
geneity, a standard terminology to describe specific aggregate
species has not yet emerged; in the following, a monomer is
defined as a single protein or peptide chain. Monomers may
exist free in solution or as complexes with other monomers in
aggregates. With aggregate we denote any assembly containing
more than one monomer, i.e. dimers, trimers and higher order
assemblies. Amyloid fibrils are linear aggregates with a repetitive
cross-beta structure which may consist of tens of thousands
of monomers. These structures are able to elongate rapidly
from their ends by association of peptides or proteins from the
solution phase. By contrast, many smaller aggregates, com-
monly termed oligomers, elongate significantly more slowly
than amyloid fibrils. The definitions for oligomers vary in the
literature. This term is often used to refer to aggregates up to a
certain size, e.g. 2–20-mers. Here, the upper limit is not always
given, and different limits may be of practical value for differ-
ent systems. The significantly lower rates of growth process for
oligomers compared to amyloid fibrils suggest that there are
significant structural differences between amyloid fibrils and
oligomers. Indeed, among the several possible definitions,
oligomers can be described as small aggregates exhibiting
different structure and lower growth rate with respect to fibrils.
It has been challenging, however, to define the smallest size of
an aggregate that possesses the characteristics of an amyloid
fibril rather than of an oligomer, since rapid elongation makes
the shortest fibrils extremely short-lived and difficult to
observe. In some reports, oligomers are defined according to
preparation method, or in terms of which substances are added
to block them from further growth. In this report we will use
the term oligomer to define the small aggregates that are
generated by the first few elongation events of nuclei without
any reference to their structure. Nuclei are the smallest aggre-
gates in the process that are stable enough that further growth
by monomer addition is faster than dissociation into monomers.
In energetic terms, nuclei are thus the species with highest
Gibbs free energy (Fig. 2) along the aggregation pathway. We
note that the schematic shown in Fig. 2 is only a simplified
version of the complex multi-dimensional free energy diagram
associated to the formation of amyloid fibrils. In addition,
nucleation reactions follow complicated pathways that populate
a cascade of intermolecular metastable species.25
It is worth pointing out that in the figures of this work,
monomeric units are illustrated as spheres without inference to
their structures, because in the frame of the mechanistic
models discussed in this paper energetic diagrams and reaction
schemes are described in a coarse-grained approach based on
the chemical potentials and the microscopic rate constants
associated to co-existing species. The chemical potentials and
the rate constants summarize the global contribution of all the
detailed molecular features of the monomeric units, which are
ultimately responsible for the aggregation propensity.
3. Kinetics of amyloid fibril formation
Nucleated self-assembly reactions, including amyloid fibril
formation, typically display sigmoidal growth kinetics.26–28
A steep transition zone is both preceded and followed by
relatively flat regions (Fig. 3a). The region before the transition
zone is referred to as the lag phase. The steep transition zone is
often called the growth phase or elongation phase as the overall
conversion rate of peptides or proteins into their amyloid forms
is greatest in this part of the reaction. The final flat region is
known as the plateau phase and represents a steady state where
the monomer concentration has reached its equilibrium value.
The onset and end of the transition can be more or less sharp
depending on the dominant underlyingmechanism,29 as discussed
further below. Importantly, however, none of these three phases
can be ascribed to a single molecular event or microscopic
process.26–29 Rather, all microscopic processes are ongoing
during all phases of the process, although their net flux varies
as governed by rate constants and the activities of reacting
species at each particular point in time. In dilute samples,
activities are approximated by concentrations.
Fig. 2 Free energy diagram of amyloid fibril formation. The nucleus is the
state with the highest free energy. Fibrils and monomers may have similar
free energy, and the total concentration of monomer governs which state
dominates at equilibrium.
Fig. 3 (a) A characteristic macroscopic aggregation curve for amyloid fibril
formation is displayed in terms of aggregate concentration (in monomer
equivalents, % of total monomer) versus time. The curve is typically divided
into a lag phase, a growth phase and a final plateau; (b) definition of t1/2, and
two alternative definitions of the lag time. Here tlag is obtained by extrapolating
the maximum derivative down to the intercept with the pre-transition
base-line; while tlag0 and t1/2 are defined as the point in time where the
signal relative to the pre-transition base line has reached 10% and 50% of
the amplitude of the transition, respectively.
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4. Definition of the lag time
The duration of the lag phase is called the lag time, tlag. However,
there are multiple ways to define the cross-over between the lag
phase and the growth phase and thus investigators use diﬀerent
methods to extract tlag from experimental data. One common
definition of tlag is the point in time where the signal relative
to the pre-transition base line has reached a chosen fraction
(e.g. 10% or 50%) of the amplitude of the transition (Fig. 3b).
If 50% is used the time point is often called the half time, t1/2 or
t0.5, rather than tlag. Another common method involves finding
the maximum derivative and extrapolating down to the intercept
with the pre-transition base-line (Fig. 3b). We will see below
that for many classes of growth reactions, in particular those
dominated by secondary nucleation, the threshold and the
extrapolation approaches result in very similar values for the
lag time of the reaction, and in particular both definitions lead
to a lag time that has an identical scaling behavior in response to
changes in the concentration of the precursor peptide or protein
in solution at the beginning of the reaction.
In some studies, an empirical sigmoidal function (logistic
function) is fitted to the data
y = y0 + A/(1 + exp(k(t  t0.5)))
where y0 is the pre-transition base line, A the amplitude of the
transition, t0.5 its midpoint and k is an apparent growth rate. By
this method the lag time is often defined as tlag = t0.5  1/2k
which is equivalent to the extrapolation from the maximal
growth rate, Fig. 3b. The logistic function is not routed
in a specific molecular level process underlying amyloid
formation and a number of other functions can also be used
to fit sigmoidal data. It has become apparent therefore, that a
strong test of a proposed reaction mechanism by comparing
rate laws with experimental data is only possible when data
acquired over a large concentration range are fitted in a global
manner.29
5. Methods to determine the lag time
A number of experimental methods can be used to follow in a
fully quantitative manner the kinetics of amyloid formation
and thus allow the lag time to be determined. These methods
monitor the decrease in the concentration of the monomeric
species or the appearance of aggregates, and can be divided
into methods that operate in situ, i.e. during the reaction, and
methods that operate ex situ, i.e. require post-handling of
aliquots taken from the aggregating mixture at well-defined
times. Many of these methods are susceptible to experimental
artifacts, and in order to obtain fully reliable data, it is
important to verify the reproducibility of the data for multiple
replicates of the reaction initiated from the same precursor
solution and to check with at least one independent method
that the observed changes in a signal are a faithful representa-
tion of the aggregation time course. In addition, these methods
can be complemented by imaging techniques, such as atomic
force microscopy (AFM)30,31 or cryo-transmission electron
microscopy (cryo-TEM),32 which can provide relevant qualita-
tive and semi-quantitative information on the fibril formation
process.
5.1 Circular dichroism spectroscopy
The monomer concentration may be monitored in situ using
circular dichroism (CD) spectroscopy relying on the diﬀerent
characteristic spectra corresponding to diﬀerent secondary
structures or random coil conformations of proteins. Thus,
monomer conversion is monitored by following the change in
the random coil signal from unstructured monomers (Fig. 4) or
other characteristic signals if monomer has some degree of
folding. The aggregate concentration may also be determined
in situ using CD spectroscopy by exploiting the fact that the
latter species are b-sheet rich (Fig. 4).33 An advantage of this method
is that monomer and fibril concentration can be quantified
simultaneously in the same sample at each time point by fitting
superimpositions of the start and end spectra.
5.2 NMR spectroscopy
Another method to monitor in situ the concentration of mono-
mer is nuclear magnetic resonance (NMR) spectroscopy (Fig. 5).
This method relies on the fact that at least some chemical shifts
of protons, nitrogens-15 or carbons-13 in the protein have
unique values in monomers. The sharp signals from fast
tumbling entities like small peptides and proteins indicate that
monomers are readily detected, whereas in aggregates only
Fig. 4 CD spectra acquired during an ongoing reaction (left). The first
spectrum (red) shows the unfolded monomer and the last spectrum (blue)
the b-sheet fibril. The monomer and fibril concentration as a function of
time (right) can be extracted by fitting superpositions of the start and end
spectra to the experimental data acquired at diﬀerent time points.
Fig. 5 NMR spectra acquired during an ongoing reaction (left). The
monomer concentration as a function of time (right) is extracted from
the peak intensities.
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mobile regions can be monitored. The monomer concentration
can be deduced from the intensity of monomer signals.34,35
Due to the low value of the gyromagnetic ratio for nuclei,
reliable monitoring of the aggregation process by NMR requires
relatively high peptide or protein concentrations, commonly in
the micromolar range.
5.3 Infrared spectroscopy
The aggregate concentration can be monitored in situ using
Fourier transform infrared (FTIR) spectroscopy relying on the
characteristic vibration frequency of hydrogen bonded back-
bone amides in extended b-sheet structure.36 FTIR spectra are
conventionally represented in terms of absorbance intensity as
a function of wave numbers, defined as the reciprocal of
the wave lengths, with units of cm1. For proteins, the major
band of interest is the amide I, which absorbs in the region
1600–1700 cm1. Different secondary structures are character-
ized by different spectra. In particular, FTIR spectra of b-sheet
structures exhibit a maximum in the region 1615–1643 cm1.
As a consequence, fibril formation can be followed by monitoring
the increase in the intensity in this characteristic range during
time, but this technique requires high protein concentration.
5.4 Fluorescence spectroscopy
Another method to monitor in situ the aggregate concentration
is intrinsic fluorescence spectroscopy relying on specific spectral
changes upon amyloid formation,37 or indirectly by the fluores-
cence from the reporter dye thioflavin T, which undergoes a
dramatic enhancement of quantum yield when bound to fibrils
(Fig. 6).38,39 ThT fluorescence was historically one of the first
assays to be used to probe the kinetics of protein aggregation
and remains one of the most widely used experimental
approaches for this purpose. Yet, despite its longstanding
and widespread use, it remains challenging to obtain fully
quantitative data using ThT fluorescence assays. This diﬃculty
is in large part due to the fact that the molecular details of the
binding of ThT to amyloid fibrils are not fully known and that
the resulting fluorescence intensity is susceptible to perturba-
tions from the presence of impurities or amorphous protein
aggregates in the system. Furthermore, the fluorescence signal
is linearly dependent on the concentration of aggregates only in
a relatively small range of ThT and protein concentrations,
which need to be optimized in each study.17
5.5 Scattering methods
Scattering methods, such as static and dynamic light scattering
and small angle X-ray scattering may be used in situ.20,40–48
These methods rely on the fact that the scattering intensity
is highly dependent on the particle size. As a consequence,
the scattering properties of aggregates are significantly larger
compared to monomers, and the formation of fibrils can be
detected by following the increase in the scattered intensity
during time. In addition, the dependence of the scattered intensity
on the scattering angles contains key information about the shape
of the objects. However, in these approaches it may be challenging
to resolve information on individual species within heterogeneous
complex mixtures from the recorded average signal, since
this procedure requires a deconvolution process that is a
well-known ill-posed problem highly sensitive to experimental
noise. Moreover, average quantities of the aggregate distribution
could be significantly biased towards larger species because of the
high dependence of the scattered intensity on the particle radius,
as described by the Rayleigh formalism. As a consequence,
for heterogeneous mixtures it is challenging to apply these
methods in a fully quantitative manner.
5.6 Ex situ methods
In an ex situ approach, aliquots of a fixed volume are collected
from an aggregating reactionmixture at diﬀerent times during the
aggregation process and separated for analysis. The advantage
of such approach relative to in situ method is the possibility to
use techniques that would perturb the aggregation reaction,
since the aliquots have been physically separated from the
reaction mixture and their treatment thus does not aﬀect the
ongoing reaction. In particular, fractionation into monomer,
fibrils and possibly also smaller aggregates at diﬀerent time
points along the reaction can be achieved using centrifugation,
filtration, chromatography, electrophoresis, or other analytical
techniques, and the quantification of individual species can
exploit for example absorbance, UV-Vis, IR fluorescence, radio-
activity, mass spectrometry with internal standard, or antibody
interactions.17,43,49
5.7 Amyloid chain amplification methods
A particularly sensitive ex situ assay for detecting the presence
of amyloid fibrils is that of the amyloid chain amplification
approach.32,50 In this method, aliquots are taken from a reaction
Fig. 6 (a) Structure of the ThT dye and (b) change in the emission fluorescence spectrum upon binding to amyloid fibrils. Typical excitation wavelength
is 440 nm; (c) the fibril formation process is monitored by recording the relative changes in the fluorescence intensity during time with respect to the
situation at time zero.
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mixture at diﬀerent times, and the fibrils contained in these
aliquots are isolated by means of filtration (Fig. 8). The concen-
tration of fibrils trapped in this manner is quantified by adding
fresh monomer solution to the retentate and comparing the
resulting aggregation kinetics, monitored through ThT fluores-
cence, with a calibration curve obtained using controlled
amounts of fibril seeds to initiate the aggregation of a solution
of monomer at the same concentration. Due to the exponential
amplification step inherent in this approach, sensitivities of at
least two orders of magnitude higher than with ThT fluores-
cence alone have been demonstrated. This method has revealed
that the fibril concentration grows with a close to exponential
rate during the lag phase, i.e. Cfibrils = A(cosh(kt)  1), where t is
time, A is a parameter related to the nucleation of new fibrils
and k is an eﬀective polymerization rate constant which reflects
the multiplication and growth rates of fibrils.32
6. The major species in solution are
monomers or fibrils at all times
Work over the past decade in diﬀerent laboratories using many of
the methods listed above has revealed a picture of the aggregation
process in which monomers or fibrils are the dominating
species during the entire time course of the aggregation process.
Monomers are the prevalent species during the lag phase and
fibrils dominate at the final plateau, while during the growth
phase their concentrations are similar. If the monomer and fibril
concentration are both measured and plotted in monomer
equivalents, the curves corresponding to the time evolution of
the decrease in the monomer concentration and the increase in
the fibril concentration follow specular sigmoidal shape, and
they cross at a time point very close to the half-time, where the
concentrations of monomer and fibril are close to 50% each
(Fig. 4b and 7). The concentrations of any intermediates, small
aggregates or oligomers, are low at all times. As a consequence,
the concentrations of intermediate species are challenging to
measure, although they can still be determined for instance by
ex situ measurements using radio-isotope labelling, separation
of the reaction mixture by size exclusion chromatography and
post-analysis by radio-counting of oligomeric versusmonomeric
fractions. In the case of Ab42, such approach revealed that the
total concentration over all oligomers (3–20mers) is always less
than 1.5% of the initial monomer load, with the maximum
appearing at the point in time where the monomer and
aggregate curves cross.17 Dimer quantification is impossible
by this method as dimers elute in the tail of the monomer peak.
7. Molecular events during the lag time
The process of amyloid formation, when initiated from a solution
of the monomeric precursor protein, requires fundamentally at
least two microscopic steps: primary nucleation frommonomers in
solution and elongation of fibrils, a process by which monomers
add to the ends of existing aggregates leading to their growth
(Fig. 9). Since the growth of fibrils occurs from their ends, any
process that is susceptible to modify the number of fibril ends in
the system has a significant impact on the overall aggregation
kinetics. In this context, a microscopic step that has been found
in several systems under agitation conditions is fragmentation
(Fig. 9). Moreover, surface catalyzed secondary nucleation from
monomers on fibril surface may also play a key role for several
systems under quiescent conditions (Fig. 9).
As mentioned above, all microscopic processes underlying
the overall reaction are active during all phases of the reac-
tion.26–29 Thus, none of the three phases seen in the overall
aggregation curve – lag phase, growth phase and final plateau
(Fig. 3) – can be ascribed to a single microscopic process as the
laws of mass action do not allow a discontinuity in the reaction
rates of any microscopic processes. A particularly interesting
case is that of primary nucleation; in a system which contains
initially a solution of purely monomeric peptides or proteins,
the concentration of aggregates is identically 0 at very early
times, and thus the fibril-dependent processes (elongation,
fragmentation and secondary nucleation) are completely
suppressed, and primary nucleation is the only molecular level
process contributing to amyloid formation that is active under
these conditions. Crucially, however, the values of the rate con-
stants that are obtained from a quantitative analysis of amyloid
growth kinetics reveal that under bulk conditions, initial nuclei
are formed through primary nucleation within milliseconds,
and thus the time span where only primary nucleation takes
place extends typically ca. 107% into the lag time; after this
point also elongation can occur, and soon afterwards also
secondary nucleation events. Additional processes, including
fragmentation, may occur not only if samples are agitated, but
also in quiescent samples depending on the stability of the
fibrils, which may vary with solution conditions. In the case of
Ab42 and Ab40 under quiescent conditions, three processes
occur with significant rate: primary nucleation elongation, and
secondary nucleation.
7.1 Millions of primary nuclei may form during the lag phase
The lag time for fibril formation is sometimes called the
nucleation period, a fact which could lead to the inference that
this time represents a waiting time for the first nuclei to appear.
This picture is sometimes seen in the literature, and may have
Fig. 7 An example of post-reaction analysis of monomer and aggregate
concentration ex situ. Samples are withdrawn from an ongoing reaction,
separated into monomers and fibrils by centrifugation, and quantified
using immunoblots, UV absorbance or ELISA assay.
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emerged because in every-day life we are used to think in small
numbers (Fig. 10).
As discussed above, however, this type of collective waiting
behavior is not in agreement with the laws of mass action and
may be possible only for single-molecule reactions. We discuss
here the lag phase in macroscopic samples studied by bulk
methods as listed above. Typical concentrations used in these
studies are 1 nM–100 mM and the sample volumes are typically
1–500 mL. Those samples thus contain 6  108–3  1016
monomers. In such large samples, the reaction is governed by
rate constants and activities, which could be well approximated
by concentrations in the low concentration regime (Fig. 9). The
large number of molecules present in such systems suggests
that statistical fluctuations should not manifest in any key
observables and that the reaction time course will be the same
each time an identical sample is studied.49,52 As discussed
above, the first nuclei appear during the very early part of the
lag phase. As an example, we consider a 100 mL solution of 4 mM
Ab42, a peptide implicated in Alzheimer’s disease, which at
t = 0 is purely monomeric. The lag time has been measured to
be 33 minutes = 2000 seconds.17,32 Using the rate constant for
primary nucleation as derived from kinetics analysis of a large
experimental data set,17,53 kn = 3  104 M1 s1, we can
calculate the number of primary nuclei formed during the
first second (i.e. the first 0.05% of the lag phase) as 1 s  3 
104 M1 s1  (4  106 M)2  104 l  6  1023 mol1 = 3 
105. The inverse of this rate represents a time scale for the
average time for the appearance of the first nucleus as 3 ms,
which is 107% of the lag time. Since the monomer concen-
tration stays close to 4 mM during the entire lag phase, the
Fig. 8 An amyloid chain amplification method. Samples are withdrawn from an ongoing reaction and separated on 200 nm filters (a). The retentates are
added to fresh monomer and the aggregation kinetics, monitored through ThT fluorescence (b), are compared to reactions seeded with controlled
amounts of fibrils at the same monomer concentration (c).32
Fig. 9 Microscopic processes underlying amyloid formation and associated rate constants and reaction rates: primary nucleation from monomers in
solution (a), elongation (growth) by monomers addition to existing aggregates (b), surface catalyzed secondary nucleation from monomers on fibril
surface (c) and fragmentation (d). In the expressions of the reaction rates in the last row, [m] refers to the free monomer concentration, [M] to the total
fibril mass concentration and [fi] to the fibril number concentration, while the rate constants are defined in the middle row.
Fig. 10 We are used to think in small numbers in a linear fashion. This
vision may induce the misleading interpretation of the lag phase as a
waiting time for fibrils to appear from a small number of oligomers.
However, typical samples used in amyloid studies contain billions of
monomers or more, and millions of primary nuclei may form during the
lag phase. Adapted from ref. 51.
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generation of primary nuclei occurs with a rate that is approxi-
mately constant until the end of the lag phase when monomer
depletion due to the growth of aggregates becomes significant.
The number of primary nuclei generated during the lag phase of
our example can thus be calculated as 2000  3  105 = 6  108.
In other words, 600 million primary nuclei have been formed
before the end of the lag phase is reached.
7.2 Secondary nuclei outnumber primary nuclei
While the calculation discussed above for the rate of formation of
primary nuclei shows that a very large number of primary nuclei
are generated during the lag phase, they may be outnumbered
by nuclei generated by secondary nucleation reactions catalysed
by the fibril surface (Fig. 11). Such fibril-catalysed nucleation
has been observed in the cases of Ab4217 and Ab40,53 as well as
a-synuclein involved in Parkinson’s disease.54 The elongation
rate, 2k+[ fi][m], governing the growth of nuclei towards long
amyloid fibrils is typically much higher than the rate for
primary nucleation, kn[m]
nC (Fig. 11a). Therefore, the first fibrils
appear almost immediately after the first nucleation event.
These fibrils provide a catalytic surface for nucleation and
because of the high rate constant, k2 = 10
4 M2 s1, the number
of nuclei generated by secondary nucleation will dominate over
primary nuclei as soon as the fibril concentration exceeds
a threshold concentration, [M*]. This concentration can be
calculated as
Secondary
nucleation
¼
Primary
nucleation
k2 M
½ ½mn2 ¼ kn½mnC
#
M½  ¼ kn
k2
¼ 3 10
4 M1 s1
104 M2 s1
¼ 3 108 M
being nC = n2 = 2 in the case of Ab42.
17 Thus, when the
aggregate concentration reaches 30 nM, the secondary nuclea-
tion rate is higher than the primary nucleation rate, as shown
by the cross of the red and blue curves in Fig. 11a. When the
nucleation rates are shown on a linear scale (Fig. 11b) the cross
is barely visible and the much higher rate of secondary com-
pared to primary nucleation during most of the reaction time
course is evident. Since both monomers and fibrils are reactants
for the secondary nucleation process, its maximal rate is reached
when both species are populated; thus secondary nucleation is
most active in the vicinity of the half time of the aggregation
reaction (Fig. 11), in the region which is typically defined
as ‘‘growth phase’’. This observation highlights the fact that
the lag phase should not be associated univocally to a nucleation
period, since in the presence of secondary nucleation processes
nucleation events are more frequent in the growth phase.
Taken together, these considerations show that nucleation
occurs from very early in the aggregation reaction and that the
duration of the lag time is in most cases not strongly influenced
by the primary nucleation rate, as would be tempting to assume
for a simple sequential process, but rather by the amplification
of primary nuclei through their growth and proliferation by
secondary nucleation processes. A corollary of this idea is that
amyloid fibrils would be expected to be found in solution
also during the lag phase, albeit at very low concentrations.
Conventional bulk assays are not suﬃciently sensitive to detect
such low concentrations, but fibrils in the nanomolar concen-
tration range can indeed be detected at least a few minutes into
the lag phase using amyloid chain amplification methods.32
7.3 Sensitivity of the lag-phase to diﬀerent microscopic
processes
Modifications of each microscopic process influence the overall
growth curve in diﬀerent characteristic manners and to diﬀerent
extents. To illustrate this concept, we have compared the aggrega-
tion curve for a 4 mM solution of Ab42 using the rate constants
obtained in 20 mM sodium phosphate at pH 8.0, with 0.2 mM
EDTA, 0.02% NaN3
17 with the curves generated by increasing or
decreasing by a factor of 10 or 100 each single rate constant
(Fig. 12). In this approach, the apparent rate constants considered
in the simulations describe any modification of the reaction
rate of the corresponding microscopic process, which may
occur by alteration of either the intrinsic rate constant asso-
ciated to the reaction or the concentrations of the species
participating to the reaction (Fig. 9).
As seen in Fig. 12, the rate constant for primary nucleation
has an influence on the length of the lag phase, which is reduced
by half at 10 fold higher rate and is doubled at 10-fold reduced
rate constant. This observation is intuitively easy to understand,
since nucleation is absolutely required for aggregates to emerge.
However, the aggregation curves shown in Fig. 12 highlight the
fact that elongation and secondary nucleation rates may have
equally strong or even a stronger influence on the length of the
lag phase, which decreases or increases if these reactions are,
respectively, increased or decreased. In particular, changes in
the elongation rate constant have dramatically larger eﬀects on
the duration of the lag phase with respect to similar changes
in the primary nucleation constant. These key observations
confirm once more that the lag phase has to be associated to
Fig. 11 Model predictions of the aggregation reaction of a 4 mM solution
of Ab42 using the rate constants as determined from kinetic analysis of a
large body of data;17,53 (a and b) microscopic reaction rates: the maximum
elongation (green line) and secondary nucleation rate (red line) occurs
close to the half-time, while primary nucleation rate (blue line) is constant
during the lag phase and decreases as monomers concentration is
reduced. The reaction rates are shown with logarithmic y-axis in (a) and
with linear y-axis in (b). The macroscopic aggregation curve is shown as a
dashed grey line with linear y-axis in both panels.
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the amplification of primary nuclei through their growth and
proliferation by elongation and secondary nucleation processes, and
should not be considered as a nucleation time only. In addition we
note that modifications of the primary nucleation rate do not aﬀect
the growth phase, while changes in elongation and secondary
nucleation modify both the lag phase and the growth phase.
8. Factors aﬀecting the length of the
lag phase
A vast number of studies have reported molecular factors
(intrinsic or extrinsic) that influence the diﬀerent microscopic
reactions and therefore the length of the lag phase. Several of
these factors have been associated to the onset and progress of
the diseases. Therefore, elucidating their role in the micro-
scopic reaction pathway can provide insights into the connec-
tion between the aggregation process and the pathology. Here
we limit to discuss the fundamental physico-chemical aspects
underlying the eﬀect of these factors on the lag-phase, while the
connection between these factors and their role in the disorders
is highly disease-specific and will not be addressed here. Intrinsic
factors found to influence the length of the lag-phase include
sequence variants such asmutations, truncation and extensions.55–59
Extrinsic factors include peptides and proteins,60–69 membranes,70,71
nanoparticles and other surfaces,72–81 poly-electrolytes and other
polymers,82,83 salt,43,84–86 small molecules,87,88 pH,54,70 temperature
or mechanical factors such as shear imposed by for example
shaking.17,89,90 Foreign surfaces, e.g. presented on nanoparticles,
can either catalyse or inhibit aggregation, leading to shortening
or lengthening of the lag phase72–75,77 depending on the
protein to surface area ratio and whether the surface is weakly
or strongly attractive.79
Based on the previous discussion, the diﬀerent molecular
factors listed above can influence the duration of the lag phase
by modifying diﬀerent microscopic events. Therefore, changes
in the lag phase should not be associated directly to modifications
of the primary nucleation rate, since elongation and secondary
nucleation rate have a dramatic eﬀect on the duration of the
lag-phase, as illustrated in Fig. 12. For instance, the length of
the lag phase is dramatically decreased if the fragmentation
rate increases, which may happen if samples are shaken,17 or if
the mechanical stability of the fibrils is reduced due to for
example impeded inter-peptide interactions within the fibril.
This is the reason why mechanical agitation is a popular method
to reduce the length of the lag phase and bring the reaction into
a more readily accessible time frame.
For the diﬀerent molecular factors, only a limited set of
studies have assigned the observed macroscopic eﬀects on the
length of the lag phase to modifications of specific microscopic
processes.91,92 In this context, kinetic analysis is emerging as a
powerful tool to correlate changes in the macroscopic reaction
profiles to modifications of the molecular events.93
We note that diﬀerent physicochemical eﬀects can underlie
the molecular mechanisms responsible for the modification of
the microscopic reactions by the diﬀerent molecular factors.
For instance, reaction rate constants depend on intrinsic
properties of the aggregating protein, such as the net charge
(the more charged the more self-repulsion) and the surface
hydrophobicity, as well as on the solution composition in terms
of pH (modulation of charges), salt (screening of self-repulsion)
and the presence of other proteins, membranes and other
surfaces, which that may serve to enhance or interfere with
the diﬀerent microscopic processes. As a consequence, the
diﬀerent molecular factors can modify the microscopic reaction
rates by aﬀecting directly the intrinsic reaction rate constant
associated to a specific microscopic event.
In other cases, the molecular factors modify the reaction rate
by changing the concentration of the reactive species rather than
the intrinsic reaction rate constant. Indeed, compounds or
proteins that bind monomers and lower the concentration of
free monomers in solution lead to an extension of the lag phase
Fig. 12 Eﬀect of individual rate constants on macroscopic aggregation growth curves. In each panel the black curve represents the simulated time
evolution of the fibril mass versus time for a 4 mM solution of Ab42 in 20 mM phosphate buﬀer, 0.2 mM EDTA, 0.02% NaN3 at pH 8.0 under quiescent
conditions according to the following rate constants: knk+ = 900 M
2 s2; k2k+ = 4  1010 M3 s2, and nucleus size nC = n2 = 2. (a) The original
calculated curve (black) and curves generated by increasing (knk+ = 9  103 M2 s2; orange and knk+ = 9  104 M2 s2; red) or decreasing (knk+ =
90 M2 s2, green; knk+ = 9 M
2 s2, blue) the rate constant for primary nucleation by a factor of 10 or 100. (b) The original curve (black) and curves
generated by increasing (k2k+ = 4 1011 M3 s2 orange; k2k+ = 4 1012 M3 s2 red) or decreasing (k2k+ = 4 109 M3 s2 green; k2k+ = 4 108 M3 s2
blue) the rate constant for secondary nucleation by a factor of 10 or 100. (c) The original curve (black) and curves generated by increasing (knk+ = 9 
103 M2 s2 and k2k+ = 4  1011 M3 s2 orange; knk+ = 9  104 M2 s2 and k2k+ = 4  1012 M3 s2 red) or decreasing (knk+ = 90 M2 s2, k2k+ = 4 
109 M3 s2, green; knk+ = 9 M
2 s2, 4  108 M3 s2, k2k+ = 4  108 M3 s2, blue) the rate constant for elongation by a factor of 10 or 100.
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in a concentration-dependent manner up to ca. 1 : 1 molar ratio
depending on the aﬃnity for monomers. One striking example
in this category is the aﬃbody Zab3 selected from a phage display
library against Ab-monomers.62 Other factors inhibit the aggre-
gation process by interacting with aggregates rather than with
monomers. Examples include proteins that extend the lag phase
at low sub-stoichiometric levels by interacting with growing
aggregates67,91,94 as well as other factors, such as the molecular
chaperone Brichos, which bind selectively to the surface of the
fibrils, thereby inhibiting secondary nucleation events. This
latter case is particularly intriguing, since this modulation of
the reaction mechanism not only leads to an extension of the lag
phase (t0.5 increases by 100%, Fig. 12b) but, most importantly,
redirects the reactive flux to a pathway that includes only primary
nucleation and elongation, thereby resulting in longer fibrils and
in a minimal generation of oligomers and toxicity.92
9. Outstanding questions
As discussed in the previous paragraphs, significant knowledge
has emerged over the last years regarding the molecular events
occurring during the lag phase of an amyloid formation process.
However, there are still several outstanding questions open for
the future, as illustrated by the following examples.
(i) A crucial issue refers to the characterization of the
oligomers accumulating during the lag-phase. This question
is of particular relevance because these low molecular weight
species are currently thought to exert toxic functions. As discussed
above, according to one of the several possible definitions,
oligomers are small aggregates exhibiting diﬀerent structure
and lower growth rate with respect to fibrils. Therefore, oligomers
can accumulate during on-going reactions, in particular in the
presence of secondary nucleation events, although they repre-
sent always a very small fraction of the species present in the
system. The experimental methods discussed in paragraph
5 have been successfully applied for the quantification of
monomers and fibrils. In contrast, there is a severe lack of
experimental techniques able to quantify oligomers, largely
because of the low concentration and the transient nature of
these species.
Ideally, building on recent advances for in situ identification
or ex situ quantification of oligomers,17,92,95,96 the development
of new experimental approaches for the in situ quantification of
these species will open the possibility to measure the reaction
orders of the microscopic events leading to their formation. In
analogy with the kinetic analysis performed with mature fibrils,
the measurement of the reaction orders of reactions involving
oligomers will provide crucial information on the microscopic
reaction mechanisms leading to the generation of these species.
Such kinetic analysis can potentially explain why oligomers
accumulate during the aggregation process, and which types of
structural conversions they undergo. These answers can clarify
for instance if the globular aggregates (‘‘globulomers’’) observed
by TEM during the lag phase for several diﬀerent synthetic
peptides are a result of structural incompatibility and frustration
in these sequence-inhomogeneous systems, or whether such
globulomers could be also found in pure samples of recombi-
nant or biologically derived peptides with high sequence homo-
geneity. Overall, improving our mechanistic understanding of
the formation of oligomers could provide insights into the
detailed molecular connection between the lag phase (and more
in general the entire aggregation process) with the pathogenesis
of most amyloid diseases.
(ii) Another outstanding question regards the molecular
events occurring during the lag phase of aggregation reactions
in complex mixtures. Indeed, bottom-up studies use clean systems
that are challenged by single chemical or physical perturbations.
Conversely, top-down studies jump all the way to aggregation
reactions in biological fluids with their huge complexity. From a
combination of these two approaches, it may be possible to address
the molecular events occurring during the lag phase in a complex
environment, and deconvolute the observed eﬀects into the
underlying perturbations resulting from long-range inter-
actions (such as, for example, electrostatic screening) and from
short-range interactions, including for instance the binding of
molecules to various species along the reaction pathway.
(iii) Lateral aggregation of proto-fibrils and fibrils is observed
in a large variety of amyloid systems. It would be important to
clarify how this additional microscopic process aﬀects elongation
and nucleation processes, and the corresponding consequences
on the duration of the lag-phase.
(iv) Lastly, since secondary nucleation of monomers on the
fibril surface dominates over primary nucleation during most
of the lag phase in diﬀerent amyloid systems, including Ab42, it
would be highly interesting to study the generality of this
microscopic process in amyloid formation reactions of various
proteins and peptides, including not only pathological but also
functional amyloids.
10. Conclusions
In summary, we have discussed the nature and the molecular
origin of the macroscopic lag-phase that is typically observed
during the formation of amyloid fibrils from a solution of soluble
monomeric peptides or proteins. After presenting currently
available physicochemical experimental techniques to measure
the lag-phase, we have discussed how the lag-phase should not
be interpreted as a waiting time for nuclei to form. Indeed, this
type of collective waiting behavior is possible only for single-
molecule reactions, while typically millions of primary nuclei
form during the lag-phase in macroscopic samples. Rather, the
lag-phase results from the combination of multiple parallel
microscopic reactions, and must be associated to the amplifi-
cation of primary nuclei through their growth and proliferation
by secondary nucleation and fragmentation processes.
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